Gut microbiome in macrolide trial, Queensland
40 faecal samples from healthy adults in Queensland, Australia, in an intervention study examining gut microbiome changes after long-term low-dose erythromycin or azithromycin therapy, with FMT used to test effects on host physiology. machine-written summary
40 samples · 40 runs · AU · Adult · 2023 · 5.86 Gbp / sample
Checked this project's papers and archive records yourself? Mark it human-verified.
what each source gave
| ✓ Sequence archive | 200 sample values (collection date, country, intervention, location region, subject id) |
| ○ Abstract / description | read; no usable statement |
| ✓ Full text | 120 sample values (antibiotic exposure, health condition, health condition detail) · PMC10433835 |
| ○ Supplementary tables | files read; no table could be matched to the samples |
| – External resources | not covered by the external resources we ingest |
| – User contribution | nothing uploaded yet |
| – Human verified | not yet checked by a person · I checked this project — verify it |
intervention — arms not resolved
Faecal microbiota transplantation design randomized_controlled_trial · population healthy_control · 4 weeks low-dose erythromycin or azithromycin in healthy adults; FMT of erythromycin-exposed mouse microbiota into germ-free mice
“healthy adults exposed to 4 weeks of low-dose erythromycin or azithromycin” — abstract:37347185 (study level; per-sample arms are in the intervention column below)
longitudinal
20 of 20 people sampled more than once (40 samples; median 2, up to 2 per person) · follow-up median 28 d (max 38 d) · median interval between samples 28 d (time from collection dates). Schedule stated by the source: “stool at baseline (pre-antibiotic) and after 4 weeks of erythromycin or azithromycin treatment” (time origin: intervention_start); stated follow-up 28 d.
Each row is one person (20 shown); dots are samples at days since that person's first sample.
Genera, mean relative abundance over 37 profiled gut samples of this project (Sandpiper SingleM profiles, GTDB R232; low-depth and non-metagenome profiles left out).
| field | samples | coverage | R1 | R2 | R3 | R4 |
|---|---|---|---|---|---|---|
| age_category | 40 | 100% | ||||
| country | 40 | 100% | 40 | |||
| health_condition | 40 | 100% | 40 | |||
| subject_id | 40 | 100% | 40 | |||
| antibiotic_exposure | 40 | 100% | 40 | |||
| collection_date | 40 | 100% | 40 | |||
| detailed_location | 40 | 100% | ||||
| health_condition_detail | 40 | 100% | 40 | |||
| intervention | 40 | 100% | 40 | |||
| location_region | 40 | 100% | 40 |
- The Impact of Long-Term Macrolide Exposure on the Gut Microbiome and Its Implications for Metabolic Control. 2023 PMID 37347185 PMC10433835 own_data
Archive description
Determining the effect of erythromycin and azithromycin on the faecal microbiota
How this project entered the registry
Classified as human gut / stool shotgun DNA metagenome of adult by deterministic_prior with confidence 0.90. Assay shotgun_dna.
- host external_curation.infant_catalog · “infant triage reason_code age_adult_only”
- body site study.title · “Alteration of the gut microbiome through long-term”
- body site study.description · “azithromycin on the faecal microbiota”
- life stage external_curation.infant_catalog · “infant triage reason_code age_adult_only”
Evidence examples (one per field × route)
| sample | field | value | route | conf. | source | quote |
|---|---|---|---|---|---|---|
| SAMN29213013 | antibiotic_exposure | no | R3 | 0.70 | paper.fulltext.methods | not received antibiotics during the preceding 3 months |
| SAMN29213013 | collection_date | 2018-03-14 | R1 | 0.90 | biosample.attribute:collection_date | 2018-03-14 |
| SAMN29213013 | country | AU | R1 | 0.90 | sample.attr.geo_loc_name | Australia:Queensland |
| SAMN29213013 | health_condition | healthy_control | R3 | 0.70 | paper.fulltext.methods | Healthy adults received a 4-week course of twice-daily oral |
| SAMN29213013 | health_condition_detail | Healthy adults | R3 | 0.70 | paper.fulltext.methods | Healthy adults received a 4-week course of twice-daily oral |
| SAMN29213013 | intervention | antibiotic | R1 | 0.70 | sample.name_rule:sample_description | IM01, Erythromycin, Baseline |
| SAMN29213013 | location_region | Queensland | R1 | 0.85 | biosample.attribute:geo_loc_name | Australia:Queensland |
| SAMN29213013 | subject_id | IM01 | R1 | 0.70 | sample.name_rule:sample_alias | IM01_V1_STOOL |
Sequencing
40 runs over 40 samples · mean 5.94 Gbp per run (median 5.86 Gbp, total 237.74 Gbp; 40 runs with a base count) · layout PAIRED 40 · platform ILLUMINA 40 · models Illumina NovaSeq 6000 (40) · 92% of runs with a Sandpiper profile · first public 2023-06-24 – 2023-06-25
Authors (13)
Choo JM first · Martin AM · Taylor SL · Sun E · Mobegi FM · Kanno T · Richard A · Burr LD · Lingman S · Martin M · Keating DJ · Mason AJ · Rogers GB last
Downloads
PRJNA851177.csv.gz (2.0 KB) · parquet (71.4 KB) — all 40 samples, every field with route and confidence · PRJNA851177_determinations.csv.gz (3.2 KB) — 320 evidence rows